RYTM241220P22500
- 0.65
- 0.000.00%
Rhythm Pharmaceuticals Newsroom
There's Reason For Concern Over Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Massive 28% Price Jump
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $69
Positive Outlook for Rhythm Pharmaceuticals Boosted by Promising Clinical Outcomes and Anticipated FDA Decision
Stifel Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $78
TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $65
Express News | Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Maintains $80 Price Target
Rhythm Pharmaceuticals Analyst Ratings
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $58 to $80
TD Cowen Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals' Advancements in Setmelanotide Trials Signal Strong Buy Rating
Buy Rating Justified for Rhythm Pharmaceuticals Due to Promising Data and Strategic Study Expansion
Rhythm Pharmaceuticals Announces Positive Weight Reduction Results in Pediatric Patients Treated With Setmelanotide in Early-Access Program and Plans New Substudy for Congenital Hypothalamic Obesity
Express News | Rhythm Pharmaceuticals Inc - to Enroll First Patients in Congenital Hypothalamic Obesity Study in Q1 2025
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients With Acquired or Congenital Hypothalamic Obesity Treated With Setmelanotide
Express News | Rhythm Pharmaceuticals Announces Five Presentations at Espe 2024, Including New Real-World Data in Pediatric Patients With Acquired or Congenital Hypothalamic Obesity Treated With Setmelanotide
Rhythm Releases Positive Imcivree Data for Younger Age Group
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$4.43 Million in Common Stock
Rhythm Pharmaceuticals Publishes Positive Phase 3 VENTURE Trial Results for Setmelanotide in Young Children With Rare Genetic Obesity Conditions
Rhythm Pharmaceuticals Announces Publication of Results From Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
Rhythm Pharmaceuticals Announces New Employment Inducement Grants